Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
NCT05098210
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive HER2 negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or does not respond to treatment (refractory) or stage III-IV non-small cell lung cancer. Personalized neo-antigen peptide vaccine is a product that combines multiple patient specific neo-antigens.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Anatomic Stage IV Breast Cancer AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Locally Advanced Cutaneous Melanoma
- Locally Advanced Mucosal Melanoma
- Metastatic Acral Melanoma
- Metastatic Conjunctival Melanoma
- Metastatic Cutaneous Melanoma
- Metastatic HER2-Negative Breast Carcinoma
- Metastatic Hormone Receptor-Positive Breast Carcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Mucosal Melanoma
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Recurrent Cutaneous Melanoma
- Recurrent HER2-Negative Breast Carcinoma
- Recurrent Hormone Receptor-Positive Breast Carcinoma
- Recurrent Lung Non-Small Cell Carcinoma
- Recurrent Mucosal Melanoma
- Stage III Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Unresectable Acral Melanoma
- Unresectable Cutaneous Melanoma
- Unresectable Lung Non-Small Cell Carcinoma
- Unresectable Mucosal Melanoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Fred Hutchinson Cancer Center
- Last updated on ClinicalTrials.gov
- July 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Washington · 1
- Fred Hutch/University of Washington Cancer Consortium · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.